ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial

IMPORTANCE: Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need. OBJECTIVE: To evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release 274-mg capsules for treatment of LID in patients with PD. DESIGN, SETTING, AND PARTICIPANTS: A rando...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Neurol
Auteurs principaux: Pahwa, Rajesh, Tanner, Caroline M., Hauser, Robert A., Isaacson, Stuart H., Nausieda, Paul A., Truong, Daniel D., Agarwal, Pinky, Hull, Keith L., Lyons, Kelly E., Johnson, Reed, Stempien, Mary Jean
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2017
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710325/
https://ncbi.nlm.nih.gov/pubmed/28604926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.0943
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires